CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a predictive test for treatment response in Multiple Sclerosis patients using genetic and clinical data. By identifying biomarkers associated with treatment outcomes, it seeks to optimize therapy and improve patient quality of life.
Multiple Sclerosis (MS) is a devastating disease of the central nervous system affecting 2.5 million worldwide. MS is a field of constant therapeutic innovation, a fact which brings hope to young adults since MS is one of the most frequent causes of severe handicap. A major unmet need is to rationalize treatment decisions.
To date, there is no way of predicting which patients will best respond to one of the 15 drugs expected on the market by 2014 and which patients are at risk of severe adverse…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, VIZCAYA BIZKAIA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Germany, MUENSTER
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
